About Us
Overview
Adolore’s Mission:
Develop Next Generation, Disease-Modifying, Non-Opioid Analgesic Gene Therapy for the Treatment of Chronic Pain
We are a biotechnology company focused on developing novel therapies for the treatment of chronic pain and other pain and nervous system conditions or disorders. Long-acting, locally-administered, non-opioid analgesic gene therapy for chronic pain.
Our two current CA8* gene therapy programs are in preclinical development for treatment of patients suffering from erythromelalgia, a form or neuropathic pain and a life-long heritable chronic pain condition representing an orphan drug disease with no approved therapy. Our programs are also in development for moderate-to-severe chronic pain due to osteoarthritis, affecting a large number of patients that are often treated with opioids due to the lack of good alternatives, thus contributing to the ongoing opioid crisis.
While many medical conditions can be a key causal factor for the development of chronic pain, it is now well accepted that for many patients, chronic pain is the disease or pain becomes the primary symptom impacting their well-being. This certainly is true for neuropathic pain, like diabetic neuropathy, post-herpetic-neuralgia (PHN) or erythromelalgia. This is also true for knee or hip osteoarthritis chronic pain, which is second only to low back pain in prevalence. Chronic severe pain is the debilitating aspect of these conditions that limits functionality, physical activity, social participation and contributes to decreased mortality. Treating the chronic pain aspect will greatly improve quality-of-life, function, as well as social and economic participation for most patients.
More about chronic pain+
Our therapeutic proteins encoded in our gene therapies (“transgenes”) are stable functional variants of the endogenous protein Carbonic Anhydrase-8 (CA8*). This protein functions inside of sensory neurons decreasing pain, and pain sensation is substantially suppressed with higher levels of CA8* inside these pain-sensing cells. Our founder, Dr. Levitt, Clinical Professor and chronic pain physician at the University of Miami, first described the role of CA8* in pain sensation and analgesic responses and pioneered incorporating the genetic code for CA8* into cutting-edge innovative gene therapy-vectors to create novel treatments for chronic pain.
More about our novel transgene technology+
Our cutting-edge, next generation gene therapy vectors are disease-free, highly selective for neuronal tissues, do not replicate (‘replication defective’), avoid immune surveillance (aiding redosing), and are locally administered with minimal off-target effects and immune-responses.
More about our novel vector technology+
Key Highlights
CA8* (*Carbonic anhydrase-8 like analgesic peptides, CA8 variants) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels that are long-acting when administered locally.